Status and phase
Conditions
Treatments
About
This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
Primary purpose
Allocation
Interventional model
Masking
162 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal